Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Lupin is currently trading at Rs. 1451.55, up by 6.20 points or 0.43% from its previous closing of Rs. 1445.35 on the BSE.
The scrip opened at Rs. 1446.05 and has touched a high and low of Rs. 1463.15 and Rs. 1421.50 respectively. So far 31,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1911.55 on 09-Feb-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1493.80 and Rs. 1421.50 respectively. The current market cap of the company is Rs. 65,564.86 crore.
The promoters holding in the company stood at 46.74%, while Institutions and Non-Institutions held 41.85% and 11.41% respectively.
Pharma Major Lupin has received tentative approval for its Olmesartan Medoximil Tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Daiichi Sankyo Inc’s Benicar Tablets, 5 mg, 20 mg and 40 mg. The company’s Olmesartan Medoximil Tablets are the AB rated generic equivalents of Daiichi Sankyo Inc’s Benicar Tablets. Olmesartan Medoximil Tablets are indicated for the treatment of hypertension, along or with other antihypertensive agents to lower blood pressure. Benicar Tablets had US sales of $1.06 billion (IMS MAT September 2016).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1455.00 |
| Dr. Reddys Lab | 5730.85 |
| Cipla | 1459.75 |
| Zydus Lifesciences | 1007.20 |
| Lupin | 1564.60 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
